Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. IBM
9. HOOD
10. DFTX

Go back to Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation

Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform

November 4, 2015 9:30 AM EST

Leerink Partners maintained a Market Perform rating and $12.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), following the company's 3Q earnings report. IRWD reported 3Q Linzess sales of ~$117m coming in modestly below Leerink's estimate of ~$121m.

Analyst Jason Gerberry commented, "IRWD reported 3Q Linzess sales of ~$117m coming in modestly... More